12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients

The study will consist of 7 clinic visits, including Screening/Baseline Visit 1 (Day 0,
which is anticipated to be the same date as Visit 6 in F202), visits after 1, 3, 6, 9, and
12 months of treatment (Visits 2-6), and a Follow-up Visit (Visit 7) scheduled within one
month after stopping study drug treatment.

Primary:

The primary objective of the study is to evaluate the long-term safety of TNX-102 SL tablets
taken daily at bedtime over 12 months in patients with FM who have completed Study
TNX-CY-F202

Secondary:

The secondary objective is to evaluate the long-term efficacy of TNX-102 SL tablets taken
daily at bedtime to control symptoms of FM

Inclusion Criteria:

1. The patient met all prior inclusion and exclusion requirements for Study F202
originally, and has had no intervening medical conditions, increased suicidal
ideation, or requirements for concomitant medications that preclude exposure to
TNX-102 SL or enrollment in the extension study.

2. The patient completed expected dosing in F202 defined as taking study medication up
to Week 12, with at least 70% compliance with medication usage (based on responses
from daily IVRS calls recorded during the F202 study) and no major protocol
violations.

3. The patient has provided written informed consent to participate in this extension
protocol.

Exclusion Criteria: